The Safety Of Tranexamic Acid In Total Joint Arthroplasty
International Journal of Orthopaedics, vol.7, pp.1221-1223, 2020 (Peer-Reviewed Journal)
- Publication Type: Article / Article
- Volume: 7
- Publication Date: 2020
- Journal Name: International Journal of Orthopaedics
- Page Numbers: pp.1221-1223
- Open Archive Collection: AVESIS Open Access Collection
- Karadeniz Technical University Affiliated: No
Abstract
TXA (Tranexamic acid) can be used to reduce blood loss in total joint arthroplasties. Due to the correlation between acute anemia occurring after total joint arthroplasties and postoperative morbidity/mortality rates, many studies were focused on different modalities to minimize blood loss. TXA can be administered by different routes: intravenous, topical, oral or a combination of these. The effective dose and administration technique of TXA is still controversial. Safety of TXA in clinical practice has been debated for a long time. TXA does not increase symptomatic or asymptomatic DVT (Deep vein thrombosis) risk. The safety of TXA is still unclarified in high-risk and comorbid patients. Prospective studies to establish stronger recommendations are necessary.